Skip to content
This GLP
Updated September 2026Fifty-two weeks, not twelve months

REMEVi review

The advertised rates belong to a fifty-two week plan, and the site promises no titration hikes.

The verdict

REMEVi publishes $199 a month for compounded semaglutide and $269 for tirzepatide on a 52-week plan, read August 2026. Month to month is $279 and $339. Coverage is 51 jurisdictions.

Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.

Category
GLP-1 telehealth
Molecule
Semaglutide · Tirzepatide
Form
Injection
States
51
From
$279/mo
Prescription
Required
Compounded
Yes — not FDA-approved
Availability
51 jurisdictions

REMEVi sells both molecules by injection. Two plan lengths are priced. The site states the price does not rise with titration.

  1. Who writes the prescription, and what do they see?

    A prescription precedes shipping. The pages state plans and terms. The clinician is not described.

    Two commitments are published rather than one, which lets a reader price either path. The claim of no titration hikes is a real promise and it applies to both.

  2. What happens when the dose goes up?

    The site states the same price every month with no titration hikes. That answers the question directly. Nothing describes clinical support at a dose increase.

  3. What the price includes

    Six months month to month is $1,674 on semaglutide. The 52-week plan is $199, so a year is $2,388 against $3,348 paid monthly. The saving is $80 a month on semaglutide and $70 on tirzepatide, for a year of commitment.

  4. What it claims, and what it cites

    Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named.

Where it holds up, and where it does not

  • Strength: No titration hikes, stated plainly
  • Strength: Both plan lengths published
  • Strength: Coverage in 51 jurisdictions
  • Limitation: The headline needs 52 weeks
  • Limitation: Month to month costs $80 more
  • Limitation: No compounding pharmacy is named

What the evidence says about this kind of treatment

The assessment above is about REMEVi. These are about the drugs it sells, and they are traced to the primary literature.

Right for
A reader committing a year who wants the rate fixed through titration.
Wrong for
A reader paying month to month from the advertised figure.

How REMEVi compares

SellerWho it suitsGo
RedBox RxReaders who want oral tirzepatide at a lower figure than the injectionSee RedBox Rx
Renlo HealthReaders who want the flat claim shown at each tier rather than asserted onceSee Renlo Health
Rewinding RXReaders who want a fixed figure and the doses it covers listedSee Rewinding RX
Compare all providers side by side →

More GLP-1 telehealth sellers reviews: MEDGmNEUVÉ HealthNextMedsNoBsRxNovaNovoCare Pharmacy

Sponsored alternative

Synergy Rx

A reader who wants the oral and injectable rates for both molecules stated up front rather than after an intake form.

Check Synergy Rx availability →

Frequently asked

Is $199 a monthly rate?
It belongs to the 52-week plan. Month to month is $279.
Does the price rise as my dose goes up?
No. The site states the same price every month with no titration hikes.
Where does REMEVi ship?
Fifty-one jurisdictions are recorded.
Is REMEVi legit?
REMEVi is a GLP-1 telehealth sellers service. Its stated availability: 51 jurisdictions. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay.
Is REMEVi expensive compared with other GLP-1 telehealth sellers?
REMEVi publishes a starting figure of $199/mo. Across the 149 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $76 to $369 with a median of $179, which puts REMEVi above the median. The other 11 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.
Glenn TorresStandards editor · Reviewed and last verified September 2026

How this was assessed. The four questions above are answered from REMEVi’s own publicly-stated model, against the published editorial methodology. No ratings are fabricated and no first-hand outcomes are claimed. A partnership never changes the assessment — see how we make money.